- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...

Atlanta (June 16 2025)-- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology, is now ...